Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., LTD.

Dotinurad Tablets belong to the antihyperuricemic therapeutic class and are a novel selective urate reabsorption inhibitor (SURI). Unlike traditional uricosuric agents, it highly selectively inhibits renal URAT1, suppressing uric acid reabsorption and promoting urinary urate excretion. It achieves effective and sustained serum uric acid lowering with limited interference on other renal transporters.

This formulation is indicated for the treatment of hyperuricemia associated with gout in adult patients.

Specifications:1 mg, 2 mg

Packaging:Alu-PVC blister, 10 tablets / blister, 3 blisters / box

Quality & Supply Advantage

Manufactured in full GMP compliance, the tablets conform to international quality standards, with stringent control over impurities, dissolution and stability. We guarantee stable supply, competitive pricing, end-to-end quality control and flexible technical support to facilitate your registration and formulation development.

As a next-generation selective URAT1 inhibitor, it supports convenient once-daily dosing and delivers reliable urate-lowering performance. Widely recognised in rheumatology practice, it addresses the growing global demand for safe and effective long-term management of gout and hyperuricemia.

We are able to supply qualified finished dosage forms, offer technology transfer and other flexible cooperation models. We welcome your enquiries for further information and potential collaboration.